Biological Treatment in Resistant Adult-onset Still's Disease: A Single-center, Retrospective Cohort Study

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2022 Aug 11

PMID 35949865

Authors

Seda Colak

Emre Tekgoz

Maghrur Mammadov

Muhammet Cinar

Sedat Yilmaz

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still's disease (AOSD) under biological treatment.

Patients And Methods: This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020. The data of the patients were obtained from the patient files. The response to the treatment was evaluated based on clinical and laboratory assessments at third and sixth follow-up visits.

Results: Interleukin (IL)-1 inhibitor was prescribed for 13 (68.4%) patients and IL-6 inhibitor prescribed for six (31.6%) patients. Seventeen (89.5%) patients experienced clinical remission.

Conclusion: Biological drugs seem to be effective for AOSD patients who are resistant to conventional therapies. Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.

References

Chen D, Lan J, Lin F, Hsieh T . Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004; 31(11):2189-98. View

Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J . Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005; 201(9):1479-86. PMC: 2213182. DOI: 10.1084/jem.20050473. View

Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O . Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (Baltimore). 2019; 98(15):e15123. PMC: 6485786. DOI: 10.1097/MD.0000000000015123. View

Reddy Munagala V, Misra R, Agarwal V, Lawrence A, Aggarwal A . Adult onset Still's disease: experience from a tertiary care rheumatology unit. Int J Rheum Dis. 2012; 15(6):e136-41. DOI: 10.1111/1756-185X.12012. View

Novick D, Kim S, Kaplanski G, Dinarello C . Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013; 25(6):439-48. DOI: 10.1016/j.smim.2013.10.014. View

Sugiura T, Maeno N, Kawaguchi Y, Takei S, Imanaka H, Kawano Y . A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther. 2006; 8(3):R60. PMC: 1526617. DOI: 10.1186/ar1930. View

Bywaters E . Still's disease in the adult. Ann Rheum Dis. 1971; 30(2):121-33. PMC: 1005739. DOI: 10.1136/ard.30.2.121. View

Yilmaz S, Karakas A, Cinar M, Coskun O, Simsek I, Erdem H . Adult onset Still's disease as a paraneoplastic syndrome--a case report and review of the literature. Bull Hosp Jt Dis (2013). 2013; 71(2):156-60. View

Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E . Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017; 8:369. PMC: 5469286. DOI: 10.3389/fphar.2017.00369. View

10.

Reihl Crnogaj M, Cubelic D, Babic A, Mayer M, Anic B . Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review. Rheumatol Int. 2020; 40(8):1317-1325. DOI: 10.1007/s00296-020-04622-4. View

11.

Liu Y, Xia C, Chen J, Fan C, He J . Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still's disease. Rheumatology (Oxford). 2020; 60(1):297-303. DOI: 10.1093/rheumatology/keaa324. View

12.

Giampietro C, Ridene M, Lequerre T, Chalumeau N, Amoura Z, Sellam J . Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2012; 65(5):822-6. DOI: 10.1002/acr.21901. View

13.

Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M . The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011; 41(2):279-85. DOI: 10.1016/j.semarthrit.2010.12.006. View

14.

Pay S, Turkcapar N, Kalyoncu M, Simsek I, Beyan E, Ertenli I . A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2005; 25(5):639-44. DOI: 10.1007/s10067-005-0138-5. View

15.

Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G . Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. J Autoimmun. 2016; 69:59-63. DOI: 10.1016/j.jaut.2016.02.010. View

16.

Seco T, Cerqueira A, Costa A, Fernandes C, Cotter J . Adult-Onset Still's Disease: Typical Presentation, Delayed Diagnosis. Cureus. 2020; 12(6):e8510. PMC: 7346332. DOI: 10.7759/cureus.8510. View

17.

Giacomelli R, Ruscitti P, Shoenfeld Y . A comprehensive review on adult onset Still's disease. J Autoimmun. 2018; 93:24-36. DOI: 10.1016/j.jaut.2018.07.018. View

18.

Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Romero E, Olive A . Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014; 66(6):1659-65. DOI: 10.1002/art.38398. View

19.

Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P . Adult-onset Still's disease. Autoimmun Rev. 2014; 13(7):708-22. DOI: 10.1016/j.autrev.2014.01.058. View

20.

Wang C, Guo S, Wang L, Shen H . Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article. Medicine (Baltimore). 2019; 98(32):e16682. PMC: 6708626. DOI: 10.1097/MD.0000000000016682. View